Article
In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms.
Antimicrobial agents and chemotherapy - 1 Jan 2012
Bulik Catharine C, Tessier Pamela R, Keel Rebecca A, Sutherland Christina A, Nicolau David P
Abstract excerpt
CXA-101 is a novel antipseudomonal cephalosporin with enhanced activity against Gram-negative organisms displaying various resistance mechanisms. This study evaluates the efficacy of exposures approximating human percent free time above the MIC (%fT > MIC) of CXA-101 with or without tazobactam and piperacillin-tazobactam (TZP) against target Gram-negative organisms, including those expressing extended-spectrum...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.